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ABSTRACT: 
3q27.2-qter deletion syndromes feature an overlapping set of terminal and interstitial deletions 
with variable congenital malformations. Diamond-Blackfan anemia (DBA) is etiologically 
heterogeneous disorder in which one cause is dominant mutations of the RPL35A gene on 3q29. 
We report a child with a 3q27.2-qter deletion that contains the RPL35A gene. She had clinical 
and laboratory features consistent with DBA and as well, an unexplained immunodeficiency 
disorder. Given these unusual findings, we reviewed other patients in the literature with 
overlapping genomic deletions. In addition, we evaluated our patient for the immunodeficiency 
disorder, RIDDLE syndrome, due to recessive mutations in the RNF168 gene on 3q29. 
A PubMed search for case reports of 3q27.2-qter overlapping deletions was performed. 
To determine if RPL35A was in the deletion region, the chromosomal regions reported were 
mapped to genomic regions using the UCSC Genome Browser. We identified 85 overlapping 
deletions, of which 6 included the RPL35A gene and all should be had DBA. Interestingly, none 
of the reported cases had immunodeficiency. To evaluate RIDDLE syndrome, we sequenced the 
remaining RNF168 gene and examined her fibroblast culture for a DNA double strand break 
repair deficiency. These results were normal, indicating that the immunodeficiency is unlikely to 
result from a RNF168 deficiency. We show that RPL35A haploinsufficiency is a cause of DBA 
and we report a novel case with 3q27.2-qter deletion and immunodeficiency. The etiology for the 
immunodeficiency remains unsolved and could be caused by an unknown gene effect or 
consequent to the DBA phenotype.  
Key words: Diamond-Blackfan anemia; RIDDLE syndrome; 3q27.2-qter deletion; RPL35A; 
RNF168; immunodeficiency 
3 
Alkhunaizi et al. 
 
INTRODUCTION: 
3q27.2-qter deletion syndromes feature an overlapping set of terminal and interstitial 
deletions with variable congenital malformations, dysmorphic features and clinical 
manifestations. DBA (MIM# 105650) is a rare dominant congenital blood disorder that often 
manifests in the first two years of life with normochromic, macrocytic anemia and selective 
deficiency of red cell precursors due to absent erythroid progenitors in the bone marrow. The 
diagnosis of DBA is based on clinical and laboratory diagnostic criteria, that include: (1) age 
younger than one year, (2) macrocytic anemia with no other significant cytopenias, (3) 
reticulocytopenia and (4) normal marrow cellularity with a paucity of erythroid precursors. 
Supporting major criteria include: (1) a gene mutation described in classical DBA and (2) a 
positive family history.  Supporting minor criteria include: (1) increased erythrocyte adenosine 
deaminase activity (eADA), (2) congenital anomalies described in classical DBA, (3) elevated 
hemoglobin F and (4) an absence of evidence of other bone marrow failure syndromes (Da Costa 
et al., 2010; Lipton and Ellis, 2010; Vlachos et al., 2008).  Currently, DBA is due to defects 
causing haploinsufficiency in at least twelve genes that encode ribosomal proteins (Gazda et al., 
2012), as well as the GATA1 gene that encodes the hematopoietic transcription factor (Sankaran 
et al., 2012). One of these genes is RPL35A gene (MIM# 180468), which plays an essential role 
in rRNA processing, ribosome biogenesis, selective cell proliferation and apoptosis (Farrar et al., 
2008). In this report, we present a patient with a de novo 12.594 Mb deletion of 3q27.2-qter that 
contains the RPL35A gene. Her clinical and laboratory features are consistent with that reported 
in this deletion and DBA but also include the unique feature of immunodeficiency. To 
investigate the cause of the immunodeficiency, we reviewed other patients in the English 
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literature with overlapping genomic deletions, sequenced the RNF168 gene and examined her 
fibroblasts for a defect in DNA double strand break (DSB) repair.  
MATERIALS AND METHODS: 
We performed a search using PubMed database from 1984 until the present date using the 
search terms “Diamond-Blackfan anemia”, “Ribosomopathy” and “RPL35A”, “3q27 deletion”, 
“3q27 microdeletion”, “3q28 deletion”, “3q28 microdeletion”, “3q29 deletion” and “3q29 
microdeletion”. The established list of articles was chosen based on their relevance and scope. 
Our search found 85 cases with overlapping genomic deletions. These cases were reported by 
(Senzaki et al., 2003; Pollazzon et al., 2009; Alvarez Arratia et al., 1984; Farrar et al., 2008; 
Willatt et al., 2005; Krepischi-Santos et al., 2006; Li et al., 2009; Ballif et al., 2008; Monfort et 
al., 2008; Città et al., 2013; Tyshchenko et al., 2009; Quintero-Rivera et al., 2010; Quarello et al., 
2012; Kuramitsu et al., 2012; Glassford et al., 2016). Genomic delineation of the deleted regions 
was determined using UCSC Genome Browser. Ethics approval was obtained according to 
institutional guidelines at the Montréal Children’s Hospital. The parents also gave consent for 
full photographs, publication and fibroblast studies. 
CLINICAL CASE: 
A 9 year old girl, was born to non-consanguineous French-Canadian parents. The 
pregnancy was complicated by oligohydramnios and reduced fetal movement. She was born at 
37 weeks; birth weight: 2346 grams (10th percentile), head circumference: 31 cm (10th percentile) 
and length: 46 cm (between 10th and 50th percentile). Her neonatal course was significant for 
transient hypoglycemia and indirect hyperbilirubinemia, which was treated with phototherapy. 
Five weeks after birth, she presented with failure to thrive that led to a diagnosis of coarctation of 
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the aorta and severe mitral stenosis, which was surgically repaired. At this time, there was severe 
anemia with hemoglobin of <56 g/L which required red blood cell transfusions. In addition, she 
was suspected to have Crohn’s disease, based on both clinical and histological evidence; for this 
she was treated with steroids which were tapered and stopped in the first year of life without 
relapse. The hemoglobin level was stable during the period of steroid treatment. Furthermore, 
she had gastro-esophageal reflux disease which eventually required a Nissen fundoplication and 
gastrostomy because of insufficient oral intake and weight loss. In her first few years of life, she 
had multiple upper respiratory tract infections and pneumonias, the latter required multiple 
hospital admissions. At 5 years of age, she was started on weekly subcutaneous immunoglobulin 
for low immunoglobulin titers and this treatment eliminated further pneumonias. In term of 
development, she has motor and language delays. She started to walk and speak at around 3 
years of age. She has expressive language delay with good receptive language skills. At 9 years, 
she has 15 single words. Her fine motor and social skills were age-appropriate. 
At the time she was evaluated for her anemia and recurrent infections, around 4 years of 
age, laboratory investigations revealed hemoglobin < 56 g/L and macrocytic anemia [mean 
corpuscular volume 97 (75.0-87.0 fL)]. The white blood cell count, differentials and platelets 
were within normal limits. Serum ferritin, iron, and transferrin saturation, vitamin B12 and folate 
level were also normal.  Hemoglobin F was elevated. A bone marrow aspiration showed a 
normocellular marrow with evidence of maturation and increased megalokaryocytes.  There was, 
however, mildly decreased myelopoiesis and erythropoiesis with mild macronormoblastic 
features. Her blood type is O+ and direct Coombs testing was negative.  Her initial B and T cell 
enumeration showed decreased overall CD8+ T cell count for age at 226 x 109/L (12%) (N: 22-
38%) with an increased CD4+/CD8+ ratio at 5.1 (1.0-2.1). On her latest evaluation at 8 years, the 
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CD8+ T count remained low.  However, her total T cell counts as well as CD4 T cell numbers 
remain normal. Although her initial B cell counts were normal, her recent counts were decreased 
at 123 x 109/L (>200 x 109/L). Immunoglobulin levels prior to immunoglobulin replacement 
therapy (IgRT) showed low IgG level at 3.0 (5.1-13.4 g/L), while IgM, IgE and IgA levels have 
remained within normal limits. She had a good protein vaccine response (diphtheria and tetanus) 
but a poor polysaccharide antigen response (Pneumovax) prompting IgRT in the context of her 
recurrent oto-sino-pulmonary infections. Although her T cell proliferation to mitogens were 
normal prior IgRT, with time she has had decreased T cell proliferative responses. Interestingly, 
she also has had decreased memory T cell subsets as well as switched memory B cells at 1%. 
Finally, her immunological phenotyping revealed an unexplained increase in her transitional 
CD4+ as well as CD8+ CD45+ RA+ ( 20% increase) and CD8+CD45+ RO+  (8% increase). She 
also had a normal functional evaluation of her classical and alternative pathways of the 
complement system. A karyotype at 650 band-resolution showed 46, XX.  However, array 
comparative genomic hybridization (aCGH) revealed a de novo12.594 Mb deletion of 3q27.2-
qter. Both parental aCGH analyses were normal. Additional biochemical tests showed normal 
urine organic acids, oligosaccharides, mucopolysaccharides. Transferrin isoelectric focusing 
showed a normal pattern of glycosylation.  After her diagnosis of DBA at 5 years of age, she was 
started on steroid treatment and a remarkable improvement in her hematological profile was 
noted with no further blood transfusions. Family history was remarkable for a paternal 
grandmother with Sjögren syndrome and hypothyroidism. Also, a paternal aunt who died at 28 
years in the context of CREST syndrome complications. In addition, a stillborn paternal female 
first cousin was reported. There was no history of anemia or immunodeficiency. 
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Physical examination at 9 years of age revealed the following growth parameters: weight: 
17.8 kg (< 0.1 percentile = 50th percentile for 4.5 year), height 111 cm (< 0.1 percentile = 50th 
percentile for 5.5 year), head circumference 47 cm (< 2nd percentile = 50th percentile for 16 
months). Pertinent findings on physical exam showed (Figure 1): hypertelorism with downward 
slanting palpebral fissures, bilateral lower lid ptosis, small mal-aligned ears with cleft earlobe on 
the left ear and Darwin’s notch on the right ear, bulbous nasal tip, flat philtrum, thin upper lip, 
small mouth and a moderately-high arched palate. She also has short finger nails with proximally 
placed thumbs but no bifid or tri-phalangeal thumbs. Cutis marmorata was also noted. 
RESULTS: 
We identified 85 patients from the literature with deletions overlapping 3q27.2-qter 
(Table I). 6 cases overlapped with the RPL35A region and had DBA. All cases showed clinical 
manifestations that include craniofacial abnormalities, developmental delay, growth deficiencies 
and variable congenital malformations that likely correspond to the associated genomic deletion. 
However, there were no patients reported with immunodeficiency. 
For the cases with DBA (Table I), two were reported by Farrar et al. (2008), one with a 
de novo 3q28-qter deletion and another with a 3q29 deletion. The first patient had anemia that 
responded to steroid treatment. He developed neutropenia, and had a bone marrow biopsy done 
that showed decreased myeloid maturation with mild dysplasia. He remained steroid dependent 
and subsequently developed persistent leukopenia. The second patient presented at 7 weeks of 
life with macrocytic anemia, reticulocytopenia, increased eADA activity and hemoglobin F 
levels and responded to steroid treatment. In these two patients, decreased expression of 
RPL35A transcripts was confirmed by quantitative RT-PCR (Farrar et al., 2008). Kuramitsu et 
al. (2012) reported one patient with an RPL35A gene deletion detected by semi-quantitative PCR 
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and confirmed by SNP arrays. This patient presented with multiple malformations including 
thumb anomalies, synostosis of radius and ulna, Cornelia de Lange-like facies, cleft palate, 
undescended testis, short stature, cerebellar hypoplasia and fetal hydrops. Quarello et al. (2012), 
identified 3 other cases with RPL35A gene deletions by multiplex ligation-dependent probe 
amplification (MLPA) assay and confirmed by RT-PCR analysis. All of these cases were 
identified on the basis of DBA features. 
Although the Farrer et al. patient above developed neutropenia and leukopenia, the 
etiology was obscured by the concomitant steroid use. However, our patient was not on steroids 
at the time the immunodeficiency presented. We considered whether our patient had an 
autosomal recessive cause of immunodeficiency, involving a deleted gene together with a second 
mutation on the remaining gene. We reviewed genes in this region (76 OMIM genes) and 
identified only RIDDLE (radiosensitivity, immunodeficiency, dysmorphic features, and learning 
difficulties) syndrome, which is caused by recessive mutations in the RNF168 gene at 3q29. The 
syndrome is associated with low immunoglobulin levels, short stature and developmental delay 
which were exhibited by our patient (Stewart et al., 2007). We sequenced the remaining RNF168 
gene and examined our patient’s fibroblasts for an inability to delocalise DSB repair proteins to 
sites of ionizing radiation (IR) induced DNA damage (Figure 2). Defects in RNF168 result in a 
failure to form IR-induced 53BP1, BRCA1, RNF168 and poly-ubiquitin foci and elevated levels 
of γ-H2AX foci at late times during DNA repair (24h post-irradiation). The lack of any gene 
alterations in the remaining RNF168 allele, normal IR-induced foci formation, and an absence of 
residual γ-H2AX foci at 24h post-irradiation indicates that our patient does not have any 
abnormalities in the RNF168-dependent DNA damage response. Thus, the underlying 
immunodeficiency is unlikely to result from a loss of RNF168 function.  
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DISCUSSION: 
DBA is a rare autosomal dominant syndrome causing bone marrow failure and is 
classified as a ribosomopathy, along with Schwachman-Diamond syndrome (SDS), congenital 
hair hypoplasia (CHH), dyskeratosis congenita (DKC) and Treacher-Collins syndrome. 
Currently, DBA can be caused by mutations in at least 12 genes that encode ribosomal proteins 
can cause DBA (Gazda et al., 2012). Dominant mutations in RPL35A account for (~3%) of DBA 
cases (Farrar and Dahl, 2011).  
We have shown that complete deletion of RPL35A can also cause DBA syndrome and 
was present in our patient as well as 6 other patients in the literature (Farrar et al., 2008; Quarello 
et al., 2012; Kuramitsu et al., 2012). The cases from the literature were identified by virtue of the 
patient being recognized with DBA, thus showing that complete gene deletions can underlie this 
disorder. In our patient, she was recognized first as having a 3q27.2-qter deletion, which then 
facilitated the correct diagnosis of her anemia. Considering the frequent use of aCGH as a 
diagnostic tool, these cases illustrate the co-occurrence of RPL35A deletions and DBA. We did 
not find any instances of an RPL35A deletion without the co-occurrence of DBA. 
Although the cause of the DBA is clarified, the etiology of the immunodeficiency 
phenotype in our patient remains unsolved. The immune dysregulation in this case affected B-
cell immunity most, requiring weekly subcutaneous IgRT, and to a lesser extent affecting T-cell 
immunity. A diagnosis of a specific antibody defect (specific polysaccharide antibody 
deficiency), or an atypical common variable immunodeficiency (with a decrease of only one 
immunoglobulin isotype) were considered in this patient. 
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We reviewed cases with overlapping deletions to identify whether an immunodeficiency 
phenotype has been associated with either the 12.594 Mb deletion or to the DBA. Although none 
of the reported overlapping deletion cases had features of an immunodeficiency disorder, there 
were 15 patients with recurrent ear infections (Table I) (Willatt et al., 2005; Ballif et al., 2008; 
Glassford et al., 2016). In the deletion region, RNF168 gene (RIDDLE syndrome) at 3q29 was a 
potential candidate. However, testing for this disorder was normal.  
Another possible, untested genomic mechanism contributing to the immunodeficiency in 
our patient is an epistatic effect on LAMP3 (MIM# 605883), located at 3q27.1 approximately 2 
Mb upstream from the deletion region. A role for LAMP3 (lysosome-associated membrane 
protein 3) in the regulation of the immune system in a patient with 3q26.33-3q27.2 deletion was 
proposed as the cause of their recurrent infections and hypogammaglobulinemia (Dasouki et al., 
2014).  
We noted that the possibility of immunodeficiency as part of the DBA syndrome itself 
has been discussed in the literature.  Finlay et al. (1982) evaluated the immunologic function in 
five patients with DBA by assessing lymphocyte enumeration, proliferation, suppression and 
growth of T cell colonies. Their investigations revealed a possible impairment of lymphocyte 
function that suggested involvement of the immune system. This was further investigated by 
Zivny et al. (2003) who studied hematopoietic progenitor differentiation in vitro and stem cell 
repopulation in vivo using samples from DBA patients and controls.  This study demonstrated a 
defective erythroid, but normal lymphoid cell repopulation in DBA patients and attributed that to 
the underlying ribosomal biogenesis defects. Rochowski et al. (2011) proposed the possibility of 
altered immunologic function in patients with inherited bone marrow failure syndromes, 
including DBA. This was interrogated by comparing neutrophil functions in patients to those in 
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healthy family members. However, no differences in neutrophil stimulation and respiratory burst 
were demonstrated. In 2015, Giri et al. assessed the immunological parameters in 33 patients 
with DBA by evaluating complete blood counts, serum immunoglobulin levels (IgG, IgA and 
IgM) and lymphocyte phenotyping (T, B and NK cells) and compared these to unaffected first-
degree relatives. Results showed that a minority of DBA patients had some parameters that were 
below the normal range, or below the range seen in the relatives. When this was adjusted to 
variables known to influence the immune response, no significant differences between the two 
groups were observed (Giri et al., 2015). Recently, a patient was reported with a clinical 
diagnosis of DBA and common variable immunodeficiency without a definite cause identified 
for the immune deficiency (Khan et al., 2011). 
Finally, there is the possibility that this child has an additional diagnosis that has not yet 
been recognized, and could be investigated by whole genome/exome sequencing. Thus, the 
relationship between DBA and immunodeficiency remains unresolved and we contribute another 
case in which an immunodeficiency might be an underlying feature of the DBA itself.  
 
CONCLUSION: 
In summary, we have presented a 9 year old girl with a novel de novo 12.594 Mb deletion 
syndrome (3q27.2-qter). In addition to DBA due to RPL35A haploinsufficiency causing the DBA 
phenotype manifestation, she had an unexplained immunodeficiency. We propose that this is 
secondary to an unknown gene effect, or to the DBA phenotype itself. Finally, applying DBA 
diagnostic criteria is warranted with those patients who carry 3q terminal deletions that overlap 
with RPL35A genomic region. 
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FIGURE LEGENDS: 
Figure 1: 9 years old girl with 3q27.2-qter deletion showing (A) hypertelorism, down slanting 
palpebral fissures, sparse eyebrows, bilateral lower lid ptosis, bilateral Dennie–Morgan fold, 
bulbous nasal tip, flat philtrum, thin upper lip and mal-aligned ears. (B) Cleft earlobe on left ear. 
(C) Darwin’s notch and tubercle on right ear. (D, E) Proximally placed thumbs with short finger 
nails. (F) Cutis marmorata. 
Figure 2: Functional immunofluorescent assays of our patient’s fibroblasts to assess formation of 
RNF168 (A), BRCA1 (B), poly-ubiquitin (C), γ-H2AX (D) and 53BP1 (E) foci following 
exposure to ionizing radiation (IR). Our patient’s fibroblasts form normal RNF168, BRCA1, 
poly-ubiquitin, γ-H2AX and 53BP1 foci following 3Gy of IR, similar to the normal fibroblast 
control cells.  
 
[Color figure can be viewed in the online issue, which is available at 
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1552-4833.] 
  
17 
Alkhunaizi et al. 
 
 
TABLE: 
Table I: Clinical and cytogenetic features reported in patients with 3q27.2-qter overlapping 
genomic deletion 
 
  
 
 
Table I: Clinical and cytogenetic features reported in patients with 3q27.2-qter overlapping genomic deletion 
Author Senzaki et 
al., 2003 
Pollazzon 
et al., 2009 
Alvarez 
Arratia et 
al., 1984 
Farrar et al., 
2008 
Willatt et 
al., 2005 
Krepischi-
santos et 
al., 2006 
Li et al., 2009 Ballif et al., 
2008 
Monfort et 
al., 2008 
Città et al., 
2013 
Tyshchenko 
et al., 2009 
Quintero-
Rivera et al., 
2010 
Quarello et 
al., 2012 
Kuramitsu 
et al. 2012 
(Glassford 
et al., 2016) 
Our patient 
Deletion region 3q27-qter 
del (N=1) 
3q27.3-
3q29 del 
(N=1) 
3q28 del 
(N=1) 
3q28-
qter del 
(N=1) 
3q29 
del 
(N=1) 
3q29 del 
(N=6) 
3q29 del 
(N=1) 
3q29 
del 
(N=1-
A)1 
3q29 
del 
(N=1-
B) 
3q29 del 
(N=14) 
3q29 del 
(N=2) 
3q29 del 
(N=4) 
3q29 del 
(N=1) 
3q29 del 
(N=2) 
3q29 del2 
(N=3) 
3q29 del2 
(N=1) 
3q29 delϪ 
(N=44) 
3q27.2-qter 
del (N=1) 
RPL35A deletion - - - + + - - - - - - - - - 3/3 + - + 
DBA  - - - + + - - - - - - - - - 3/3 + - + 
Growth Delay + - + N/A N/A 1/6 + N/A - N/A N/A - - 1/2 N/A + 17/44 + 
Short stature + - N/A N/A N/A 1/6 + N/A - N/A N/A - - 1/2 N/A + N/A + 
Microcephaly + - + N/A N/A 1/6 + N/A - 5/14 N/A 1/4 - 1/2 N/A N/A N/A + 
Developmental delay 
(mental, motor or 
speech) 
+ + + + N/A 6/6 + + - + + 4/4 + 2/2 N/A N/A 17/42 + 
Dysmorphic features  
Eyes + + + + N/A 1/6 + N/A + N/A + 4/4 + 1/2 N/A N/A N/A + 
Ears + + N/A + N/A 1/6 + N/A + 4/14 + 4/4 - 1/2 N/A N/A N/A + 
Nose + + N/A N/A N/A N/A N/A N/A + 4/14 + 4/4 + 2/2 N/A N/A N/A + 
Mouth + + + N/A N/A 1/6 + N/A + 2/14 + 4/4 + 1/2 N/A + 1/42 + 
Fingers, toes + + + N/A N/A 4/6 N/A N/A + 0/14 N/A 2/4 - 2/2 N/A + N/A + 
Congenital anomalies  
Heart + + + + N/A N/A N/A + + N/A + 1/4 - - N/A N/A 11/42 + 
CNS N/A + N/A N/A N/A 1/6 N/A N/A N/A 2/14 N/A 2/4 N/A 1/2 N/A + N/A + 
Gastrointestinal N/A N/A N/A N/A N/A N/A N/A N/A + N/A N/A N/A + 1/2 N/A N/A 28/41 + 
Genitourinary N/A N/A N/A + N/A N/A N/A N/A N/A 1/14 N/A 1/4 N/A - N/A + Genitourina
ry: 3/40, 
Renal: 2/38 
- 
Musculoskeletal N/A + N/A N/A + 2/6 N/A N/A N/A 1/14 N/A 3/4 - 1/2 N/A + N/A + 
Immunology   
Immunodeficiency ƚ N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A + 
Recurrent otitis N/A N/A N/A N/A N/A 1/6 N/A N/A N/A 1/14 N/A N/A - - N/A N/A 13/41 + 
+ : present; - : not present; N/A : not available or reported; N : number of cases; 11-A is the father of 1-B, ƚ low lymphocytes or immunoglobulin; 2 the extent of the deletion beyond the RPL35A gene in either direction is unknown. 
Ϫ: In the Glassford report, it is not clear if any of these patients were previously reported. 

 
